uniQure Provides Positive Recommendation to Advance P- I/II Study of AMT-130 for Huntington Disease

Shots:

• The DSMB recommended continued the dosing in the P- I/II clinical trial assessing AMT-130 in patients with a second higher-dose cohort, after review safety data from the first cohort of ten patients
• The first cohort of P- I/II trial for AMT-130 in 10 patients out of which six patients received treatment with AMT-130 and four patients received imitation surgery for early manifest HD. UniQure will now begin to enroll patients in the higher-dose cohort of the trial
• The company initiates clinical development of the therapy in Europe in H2’21 and share initial imaging and biomarker data from the US clinical trial in 2021

Click here to­ read full press release/ article | Ref: Globe Newswire | Image: STAT News